Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Feels The Weight Of FDA’s “Approvable” Letter For Rimonabant

Executive Summary

FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris

You may also be interested in...



Sanofi Seeks Further FDA Input Following Zimulti NDA Withdrawal

Sanofi-Aventis intends to resubmit its NDA for Zimulti (rimonabant) pending clarification of FDA's questions regarding its obesity claim. The firm announced it was withdrawing the application June 29, roughly two weeks after the agency's Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted against approval of the cannabinoid-1 receptor antagonist for weight loss

Sanofi Seeks Further FDA Input Following Zimulti NDA Withdrawal

Sanofi-Aventis intends to resubmit its NDA for Zimulti (rimonabant) pending clarification of FDA's questions regarding its obesity claim. The firm announced it was withdrawing the application June 29, roughly two weeks after the agency's Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted against approval of the cannabinoid-1 receptor antagonist for weight loss

Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval

If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes

Related Content

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel